Wednesday, April 20, 2022 The CCTG MYC2 study: Phase III Study of SC Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study S1803)” has been centrally activated. Daratumumab is an anti CD38 monoclonal antibody which is commonly used to treat multiple myeloma. Typically daratumumab is given intravenously in Canada - subcutaneous (sc) daratumumab is being used in this study. This trial will compare a standard of care maintenance strategy (lenalidomide) with a novel maintenance (lenalidomide + subcutaneous daratumumab/rHuPH20) to answer the question – what is the best maintenance regimen? After two years of maintenance with either regimen, there will then be a second randomization to either continuous maintenance or stopping maintenance, based on MRD status (among those who have achieved VGPR). This will help determine the optimal duration of maintenance. The use of an MRD directed strategy is a novel approach also being tested to guide therapeutic decisions in this setting. The network Canadian Chair for this trial is Dr. Chris Venner from Alberta Health Services,and he is also the CCTG Co-Chair of the Myeloma Sub-Committee. To find out more please visit the CCTG MYC2 trial page or reach out to the central office study team.
